979 related articles for article (PubMed ID: 30337183)
1. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M;
Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
Kobayashi T; Saji T; Otani T; Takeuchi K; Nakamura T; Arakawa H; Kato T; Hara T; Hamaoka K; Ogawa S; Miura M; Nomura Y; Fuse S; Ichida F; Seki M; Fukazawa R; Ogawa C; Furuno K; Tokunaga H; Takatsuki S; Hara S; Morikawa A;
Lancet; 2012 Apr; 379(9826):1613-20. PubMed ID: 22405251
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors of Coronary Artery Aneurysms in Kawasaki Disease with a Low Risk of Intravenous Immunoglobulin Resistance: An Analysis of Post RAISE.
Iio K; Morikawa Y; Miyata K; Kaneko T; Misawa M; Yamagishi H; Miura M
J Pediatr; 2022 Jan; 240():158-163.e4. PubMed ID: 34461064
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.
Hamada H; Suzuki H; Onouchi Y; Ebata R; Terai M; Fuse S; Okajima Y; Kurotobi S; Hirai K; Soga T; Ishiguchi Y; Okuma Y; Takada N; Yanai M; Sato J; Nakayashiro M; Ayusawa M; Yamamoto E; Nomura Y; Hashimura Y; Ouchi K; Masuda H; Takatsuki S; Hirono K; Ariga T; Higaki T; Otsuki A; Terauchi M; Aoyagi R; Sato T; Fujii Y; Fujiwara T; Hanaoka H; Hata A;
Lancet; 2019 Mar; 393(10176):1128-1137. PubMed ID: 30853151
[TBL] [Abstract][Full Text] [Related]
5. Risk Factors of Coronary Artery Abnormalities and Resistance to Intravenous Immunoglobulin Plus Corticosteroid Therapy in Severe Kawasaki Disease: An Analysis of Post RAISE.
Miyata K; Miura M; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H
Circ Cardiovasc Qual Outcomes; 2021 Feb; 14(2):e007191. PubMed ID: 33541111
[TBL] [Abstract][Full Text] [Related]
6. Intravenous immunoglobulin for the treatment of Kawasaki disease.
Broderick C; Kobayashi S; Suto M; Ito S; Kobayashi T
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD014884. PubMed ID: 36695415
[TBL] [Abstract][Full Text] [Related]
7. Fever pattern and C-reactive protein predict response to rescue therapy in Kawasaki disease.
Nakagama Y; Inuzuka R; Hayashi T; Shindo T; Hirata Y; Shimizu N; Inatomi J; Yokoyama Y; Namai Y; Oda Y; Takamizawa M; Harita Y; Oka A
Pediatr Int; 2016 Mar; 58(3):180-184. PubMed ID: 26222760
[TBL] [Abstract][Full Text] [Related]
8. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
Burns JC; Roberts SC; Tremoulet AH; He F; Printz BF; Ashouri N; Jain SS; Michalik DE; Sharma K; Truong DT; Wood JB; Kim KK; Jain S;
Lancet Child Adolesc Health; 2021 Dec; 5(12):852-861. PubMed ID: 34715057
[TBL] [Abstract][Full Text] [Related]
9. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[TBL] [Abstract][Full Text] [Related]
10. Bradycardia Associated with Prednisolone in Children with Severe Kawasaki Disease.
Nagakura A; Morikawa Y; Sakakibara H; Miura M
J Pediatr; 2017 Jun; 185():106-111.e1. PubMed ID: 28343657
[TBL] [Abstract][Full Text] [Related]
11. Intravenous immune globulin plus corticosteroids in refractory Kawasaki disease.
Jibiki T; Kato I; Shiohama T; Abe K; Anzai S; Takeda N; Yamaguchi KI; Kanazawa M; Kurosaki T
Pediatr Int; 2011 Oct; 53(5):729-735. PubMed ID: 21342358
[TBL] [Abstract][Full Text] [Related]
12. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.
Nanishi E; Nishio H; Takada H; Yamamura K; Fukazawa M; Furuno K; Mizuno Y; Saigo K; Kadoya R; Ohbuchi N; Onoe Y; Yamashita H; Nakayama H; Hara T; Ohno T; Takahashi Y; Hatae K; Harada T; Shimose T; Kishimoto J; Ohga S; Hara T
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28684643
[TBL] [Abstract][Full Text] [Related]
13. High incidence of adrenal suppression in children with Kawasaki disease treated with intravenous immunoglobulin plus prednisolone.
Goto M; Miyagawa N; Kikunaga K; Miura M; Hasegawa Y
Endocr J; 2015; 62(2):145-51. PubMed ID: 25342092
[TBL] [Abstract][Full Text] [Related]
14. Importance of C-reactive protein level in predicting non-response to additional intravenous immunoglobulin treatment in children with Kawasaki disease: a retrospective study.
Iwashima S; Kimura M; Ishikawa T; Ohzeki T
Clin Drug Investig; 2011; 31(3):191-9. PubMed ID: 21456105
[TBL] [Abstract][Full Text] [Related]
15. Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease.
Kobayashi T; Inoue Y; Otani T; Morikawa A; Kobayashi T; Takeuchi K; Saji T; Sonobe T; Ogawa S; Miura M; Arakawa H
Pediatr Infect Dis J; 2009 Jun; 28(6):498-502. PubMed ID: 19504733
[TBL] [Abstract][Full Text] [Related]
16. Serum tenascin-C predicts resistance to steroid combination therapy in high-risk Kawasaki disease: a multicenter prospective cohort study.
Yoshikane Y; Okuma Y; Miyamoto T; Hashimoto J; Fukazawa R; Kato T; Takeda A; Suda K; Matsushita T; Hiroe M; Imanaka-Yoshida K
Pediatr Rheumatol Online J; 2021 Jun; 19(1):82. PubMed ID: 34090475
[TBL] [Abstract][Full Text] [Related]
17. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy.
Hashino K; Ishii M; Iemura M; Akagi T; Kato H
Pediatr Int; 2001 Jun; 43(3):211-7. PubMed ID: 11380911
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease.
Lim YJ; Jung JW
Yonsei Med J; 2014 Sep; 55(5):1260-6. PubMed ID: 25048483
[TBL] [Abstract][Full Text] [Related]
19. Role of glucocorticoids in Kawasaki disease.
Miura M
Int J Rheum Dis; 2018 Jan; 21(1):70-75. PubMed ID: 29105310
[TBL] [Abstract][Full Text] [Related]
20. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
Eleftheriou D; Moraes YC; Purvis C; Pursell M; Morillas MM; Kahn R; Mossberg M; Kucera F; Tulloh R; Standing JF; Swallow V; McCormack R; Herberg J; Levin M; Wan M; Klein N; Connon R; Walker AS; Brogan P
Trials; 2023 Jan; 24(1):60. PubMed ID: 36703139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
